# Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer

> **NCT00729586** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 73 (actual)

## Conditions studied

- Endometrial Carcinoma
- Recurrent Uterine Corpus Carcinoma
- Stage IIIA Uterine Corpus Cancer
- Stage IIIB Uterine Corpus Cancer
- Stage IIIC1 Uterine Corpus Cancer
- Stage IIIC2 Uterine Corpus Cancer
- Stage IVA Uterine Corpus Cancer
- Stage IVB Uterine Corpus Cancer

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Megestrol Acetate
- **DRUG:** Tamoxifen Citrate
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT00729586
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2019-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00729586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00729586, "Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00729586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*